Study guide
2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial)
Certified Genetic Counselor CGC
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics
2 Domain 1A: Clinical Information
1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review
3 Domain 1B: Human Development
1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development
4 Domain 1C: Chromosomal & Contiguous Gene Syndromes
1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)
5 Domain 1C: Hereditary Cancer Syndromes
1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition
6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions
1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework
7 Domain 2A: Pedigree & Risk Assessment
2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans
8 Domain 2B: Inheritance Principles
2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype
9 Domain 2B: Population Genetics & Variation
2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility
10 Domain 3A: Test Methodologies
3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics
11 Domain 3A: Variant Interpretation
3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework
12 Domain 3B: Testing Options
3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing
13 Domain 3C: Reproductive Risk Management
3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)
14 Domain 4A: Counseling Foundations
4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility
15 Domain 4A: Theories, Coping & Dynamics
4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics
16 Domain 4B: Communication & Education
4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making
17 Domain 5A–B: Finance & Client Resources
5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery
18 Domain 5C: Legal & Regulatory Requirements
5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing
19 Domain 5D: Professional Frameworks
5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education
20 Integration & Exam Strategy
6.1 Integrating Domains in Case-Based Practice & Exam Strategy
2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial)
Key Takeaways Explain This Topic AI
Mitochondrial DNA disorders are maternally transmitted; fathers with mtDNA disease generally do not pass mtDNA to offspring, while heteroplasmy and tissue thresholds drive variable severity
Genomic imprinting is parent-of-origin silencing; the same 15q11.2-q13 region yields Prader-Willi or Angelman phenotypes depending on whether paternal or maternal contribution is missing
Multifactorial traits reflect combined genetic liability and environmental exposures; the threshold model explains why recurrence rises with more affected relatives and greater severity
Heritability estimates the proportion of population phenotypic variance attributable to genetic differences—it is not an individual’s percent chance of developing disease
Non-Mendelian counseling fails when mitochondrial, imprinting, or multifactorial patterns are forced into 50%/25% single-gene scripts
Last updated: August 2026
2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial)
Quick Answer: When pedigrees refuse Mendelian math, reach for three board frameworks: maternal mitochondrial (mtDNA) inheritance , genomic imprinting (parent-of-origin effects) , and multifactorial/threshold disease with heritability as a population concept—not a personal probability.
These mechanisms appear across Domain 1 conditions and Domain 2 risk talks. Keep imprinting conceptual here; deep PWS/AS phenotype teaching belongs with chromosomal/imprinting syndrome chapters.
Mitochondrial Inheritance
Human mtDNA is transmitted through the oocyte . Clinical consequences:
Principle Counseling implication
Maternal transmission A mother with a pathogenic mtDNA variant can transmit it to all children; a father with mtDNA disease typically does not transmit mtDNA disease to offspring
- Heteroplasmy Cells/tissues may carry a mixture of mutant and wild-type mtDNA
- Threshold effect Clinical disease often appears only when mutant load exceeds a tissue-specific threshold
- Variable load Heteroplasmy can differ among siblings and among tissues in one person → unpredictable severity
- Bottleneck A maternal bottleneck during oogenesis can shift heteroplasmy dramatically between generations
Exam vignette cues: maternal lineage affected (mother, siblings, maternal aunts/uncles/cousins); no paternal transmission of the mtDNA trait; overlapping “mitochondrial” phenotypes (stroke-like episodes, myopathy, lactic acidosis, hearing loss, diabetes—pattern recognition, not a single pathognomonic list).
Nuclear vs mtDNA: Many mitochondrial diseases are caused by nuclear genes (Mendelian AR/AD/XL). Do not label every OXPHOS disorder “maternal inheritance.” Ask whether the variant is in mtDNA or nuclear DNA before quoting maternal-only transmission.
Practical counseling limits: Even with known maternal heteroplasmy, predicting a fetus’s load and phenotype is imprecise. Discuss reproductive options (including, where available and appropriate, mitochondrial replacement contexts as emerging/specialized topics) without overstating predictive precision of a single heteroplasmy percentage.
Genomic Imprinting (Parent-of-Origin Effects)
Imprinting means certain genes are expressed from only the maternal or only the paternal allele because of epigenetic marks established in gametogenesis.
- Concept Board meaning
- Parent-of-origin dependence Deletion/UPD/epimutations matter based on which parent contributed the error
- Same locus, different disease Opposite phenotypes from loss of paternal vs maternal contribution
Not Mendelian segregation alone Recurrence depends on mechanism (deletion vs UPD vs imprinting center vs single-gene), not a blanket 50%
Clinical Link: Prader-Willi and Angelman (Mechanism Level)
Chromosome region 15q11.2-q13 is the classic teaching pair:
Condition Core genomic idea (keep brief)
Prader-Willi syndrome (PWS) Lack of paternal contribution at the imprinted interval (paternal deletion, maternal uniparental disomy 15, or imprinting defect)
Angelman syndrome (AS) Lack of functional maternal UBE3A contribution (maternal deletion, paternal UPD 15, imprinting defect, or maternal UBE3A pathogenic variant)
Counseling point without duplicating syndrome depth: Mechanism determines recurrence. A de novo paternal deletion causing PWS has different recurrence implications than a familial imprinting-center variant or a maternal UBE3A variant causing AS. Always map parent of origin + molecular class before quoting numbers.
Other imprinting disorders (Beckwith-Wiedemann, Russell-Silver, and related growth syndromes) follow the same logic: phenotype tracks which parental allele is missing, duplicated, or epigenetically mis-set.
Multifactorial Inheritance and the Threshold Model
Multifactorial traits arise from combined polygenic liability plus environment (teratogens, nutrition, stochastic developmental noise, etc.). Congenital anomalies such as neural tube defects, cleft lip/palate, and many isolated heart defects are taught this way when not explained by a major Mendelian or chromosomal cause.
Threshold Model
Imagine a continuous liability distribution . Disease appears when liability crosses a threshold .
- Observation Threshold-model explanation
- Recurrence higher than population baseline after one affected child Family shares elevated liability
- Recurrence rises with ≥2 affected relatives Greater shared genetic/environmental liability
- More severe or bilateral defects → higher recurrence More extreme liability in the family
Sex-differential thresholds The less frequently affected sex may need higher liability to manifest → higher recurrence in relatives when the rare-sex proband is affected
Empiric risks (published tables for specific anomalies) are used because single-locus Mendelian fractions do not apply. Quote condition-specific empiric figures; do not invent “25% multifactorial risk.”
Heritability at Board Level
Heritability (h²) estimates the fraction of phenotypic variance in a population attributable to genetic variance under a given environment. Critical clarifications:
- Heritability is Heritability is not
- A population statistic for a trait in a context An individual’s percent chance of disease
Sensitive to environmental variation in the studied population Proof that environment is unimportant when h² is high
Useful for understanding twin/family correlation patterns A substitute for Mendelian counseling when a major gene is identified
High heritability for height or schizophrenia-spectrum liability does not mean a counselor can tell one client “your risk is h².” For counseling, pair family history with empiric or Mendelian/genomic data appropriate to the case.
Side-by-Side: When to Leave Mendelian Scripts
Clue in the case Prefer this framework
Maternal-line mitochondrial features; no father-to-child mtDNA transmission mtDNA inheritance + heteroplasmy/threshold
Opposite syndromes from 15q depending on parent of origin; UPD mentioned Imprinting
Isolated common birth defect; mildly elevated sibling recurrence; no syndrome pattern Multifactorial / empiric risks
Twin studies or “highly heritable” language without a gene Heritability as population variance—not personal odds
Session Structure
Decide whether the pedigree fits Mendelian, mitochondrial, imprinting, or multifactorial first.
For mtDNA, teach maternal transmission + heteroplasmy unpredictability without nuclear-gene confusion.
For imprinting, name parent of origin and send mechanism-specific recurrence to the molecular result.
For multifactorial anomalies, use threshold/empiric language and avoid forcing 50%/25%.
Define heritability carefully if a stem uses the word—boards test misconceptions as often as definitions.
Non-Mendelian fluency prevents the most common Domain 2B error: applying autosomal recessive math to every “unaffected parents, affected child” vignette without checking mitochondria, imprinting, de novo dominant disease, or multifactorial liability.